Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Onur Durmaz, Aslı Büyükçapar, Berçem Arinci, Can Inceman & Neslihan Akkişi Kumsar. (2023) Investigating differences of medications in hospitalized schizophrenia and schizoaffective disorder patients: impact of substance use. Journal of Substance Use 28:4, pages 602-609.
Read now
Read now
Renato de Filippis, Pasquale De Fazio, Raffaele Gaetano, Luca Steardo, Clemente Cedro, Antonio Bruno, Rocco Antonio Zoccali & Maria Rosaria Anna Muscatello. (2021) Current and emerging long-acting antipsychotics for the treatment of schizophrenia. Expert Opinion on Drug Safety 20:7, pages 771-790.
Read now
Read now
Xue Song, Antoine C. El Khoury, Matthew Brouillette, David Smith & Kruti Joshi. (2019) Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia. Journal of Medical Economics 22:11, pages 1105-1112.
Read now
Read now
Mallik Greene, Tingjian Yan, Eunice Chang, Ann Hartry, Maëlys Touya & Michael S. Broder. (2018) Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. Journal of Medical Economics 21:2, pages 127-134.
Read now
Read now
Tingjian Yan, Mallik Greene, Eunice Chang, Ann Hartry, Maëlys Touya & Michael S. Broder. (2018) All-cause hospitalization and associated costs in patients with schizophrenia or bipolar disorder initiating long-acting injectable antipsychotics. Current Medical Research and Opinion 34:1, pages 41-47.
Read now
Read now
Jean-Michel Azorin, Nicolas Simon, Marc Adida & Raoul Belzeaux. (2016) Pharmacological treatment of schizophrenia with comorbid substance use disorder. Expert Opinion on Pharmacotherapy 17:2, pages 231-253.
Read now
Read now
AlanI. Green. (2012) Long-Acting Injectable Antipsychotic Medications in Patients With Comorbid Schizophrenia and Substance Use Disorders. Journal of Dual Diagnosis 8:1, pages 62-63.
Read now
Read now
Articles from other publishers (15)
Joel Pidutti, Ari B. Cuperfain, Eric Solway, Virginia Duff & Erin Lurie. (2023) Initiation of Extended-release Depot Buprenorphine in a Patient Subject to a Community Treatment Order for Both Antipsychotic and Opioid Agonist Treatments. Journal of Addiction Medicine 17:6, pages 742-744.
Crossref
Crossref
Stefania Chiappini, Alessio Mosca, Andrea Miuli, Francesco Di Carlo, Giacomo d'Andrea, Alessandra Napolitano, Monica Santangelo, Corradina Esposito, Anna Rosazza, Elena Haefele, Gilberto Di Petta, Mauro Pettorruso, Stefano L. Sensi & Giovanni Martinotti. (2023) Aripiprazole once monthly as a maintenance treatment for patients with schizophrenia and alcohol/substance use disorder: an observational, real-world study. Advances in Dual Diagnosis.
Crossref
Crossref
Anna Maria Auxilia, Massimiliano Buoli, Alice Caldiroli, Greta Silvia Carnevali, Agnese Tringali, Roberto Nava, Massimo Clerici & Enrico Capuzzi. (2023) High Rate of Discontinuation during Long-Acting Injectable Antipsychotic Treatment in Patients with Psychotic Disorders. Biomedicines 11:2, pages 314.
Crossref
Crossref
Giovanni Martinotti, Stefania Chiappini, Alessio Mosca, Andrea Miuli, Maria Chiara Santovito, Mauro Pettorruso, Valentin Skryabin, Stefano L. Sensi & Massimo Di Giannantonio. (2022) Atypical Antipsychotic Drugs in Dual Disorders: Current Evidence for Clinical
Practice. Current Pharmaceutical Design 28:27, pages 2241-2259.
Crossref
Crossref
Scott T. Ewing, Chris Dorcely, Rivka Maidi, Gulsah Paker, Eva Schelbaum & Robert Ranaldi. (2021) Low‐dose polypharmacology targeting dopamine D1 and D3 receptors reduces cue‐induced relapse to heroin seeking in rats. Addiction Biology 26:4.
Crossref
Crossref
Michael Ming Cheuk Wong, Albert Kar Kin Chung, Timothy Ming Hong Yeung, David Tai Wai Wong, Che Kin Lee, Eric Lai, Gloria Fong Yeung Chan, Gregory Kai Lok Mak, Jessica Oi Yin Wong, Roger Man Kin Ng & Ki Yan Mak. (2021) Guidance on the clinical understanding and use of long‐acting injectable antipsychotics in Schizophrenia: Hong Kong Consensus Statements. CNS Neuroscience & Therapeutics 27:S1, pages 5-11.
Crossref
Crossref
Marc Krause, Maximilian Huhn, Johannes Schneider-Thoma, Irene Bighelli, Katharina Gutsmiedl & Stefan Leucht. (2019) Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis. European Neuropsychopharmacology 29:1, pages 32-45.
Crossref
Crossref
Tingjian Yan, Mallik Greene, Eunice Chang, Maëlys Touya & Michael S Broder. (2018) Impact of initiating long-acting injectable antipsychotics on hospitalization in patients with bipolar I disorder. Journal of Comparative Effectiveness Research 7:11, pages 1083-1093.
Crossref
Crossref
Kruti Joshi, Marie-Hélène Lafeuille, Rhiannon Kamstra, Sean Tiggelaar, Patrick Lefebvre, Edward Kim, Yong Yue & Neeta Tandon. (2018) Real-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefits. Journal of Comparative Effectiveness Research 7:2, pages 121-133.
Crossref
Crossref
Serena Luchenski, Nick Maguire, Robert W Aldridge, Andrew Hayward, Alistair Story, Patrick Perri, James Withers, Sharon Clint, Suzanne Fitzpatrick & Nigel Hewett. (2018) What works in inclusion health: overview of effective interventions for marginalised and excluded populations. The Lancet 391:10117, pages 266-280.
Crossref
Crossref
F. Chartier, F. Rouillon, L. Berggren, I. Jamonneau, B. Falissard & P.M. Llorca. (2017) Follow-up study of patients treated with olanzapine pamoate in France in real-life treatment situation. L'Encéphale 43:4, pages 303-310.
Crossref
Crossref
Peter Bosanac & David Jonathan Castle. (2018) Why are long-acting injectable antipsychotics still underused?. BJPsych Advances 21:2, pages 98-105.
Crossref
Crossref
Sofia Brissos, Miguel Ruiz Veguilla, David Taylor & Vicent Balanzá-Martinez. (2014) The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Therapeutic Advances in Psychopharmacology 4:5, pages 198-219.
Crossref
Crossref
Michael J. Vitacco & Peter F. Buckley. (2013) Substance Use Comorbidity in Patients with Schizophrenia. Psychiatric Annals 43:10, pages 454-457.
Crossref
Crossref
Maju Mathew Koola, Douglas Lee Boggs, Deanna Lynn Kelly, Fang Liu, Jared Allen Linthicum, Hailey Elaine Turner, Robert Patrick McMahon & David Alan Gorelick. (2013) Relief of cannabis withdrawal symptoms and cannabis quitting strategies in people with schizophrenia. Psychiatry Research 209:3, pages 273-278.
Crossref
Crossref